Two China Biopharmas Strike $65 Million Deal for Rights to Cell Therapy
October 06, 2020 at 07:03 AM EDT
Guangzhou Link Health Pharma and Shenzhen Pregene Biopharma announced a $65 million deal to acquire China/Asia rights to a cell therapy for bone fractures developed by Bone Therapeutics of Brussels . ALLOB is an allogeneic, off-the-shelf product manufactured by a proprietary process using cultured bone marrow mesenchymal stem cells from healthy adult donors. ALLOB has completed two European Phase IIa tests showing safety and efficacy. ChinaBio®, in partnership with Agile Capital, represented Bone Therapeutics in the transaction. More details.... Stock Symbol: (Euronext: BOTHE) Share this with colleagues: // //
